HD-OPM Archive
Topics › PCSK9, ezetimibe & newer drugs

2025 ESC/EAS update: where ezetimibe, bempedoic acid, PCSK9 drugs and inclisiran fit

Louis Nervegna · Oct 19, 2025 · ♥ 5 reactions · 10 comments · original Facebook post
PCSK9, ezetimibe & newer drugsLDL, ApoB & lipid panelGuidelines, policy & public health
AI summary & key facts

A shared graphic summarizes the 2025 ESC/EAS dyslipidaemia guideline update on add-on LDL-lowering after statins. Ezetimibe is the first oral add-on, bempedoic acid suits statin intolerance, PCSK9 antibodies give the biggest reductions in very-high-risk patients, and inclisiran offers twice-yearly dosing for adherence.

#pcsk9HD #ezetimibeHD #bempedoicacidHD #inclisiranHD #statinsHD #guidelinesHD #ldlHD

Research cited

Not at LDL-C Goal? Here’s Where the New Agents Fit in 2025.

Despite statin therapy, many patients require additional LDL-C reduction. The 2025 ESC/EAS update refines the role of newer agents:

· Ezetimibe: First-line oral add-on; ~20% reduction.
· Bempedoic Acid: Oral option for statin intolerance; ~23% alone, ~38% with ezetimibe.
· PCSK9 mAbs: High-efficacy injectables (~50-60% reduction) for very high-risk patients.
· Inclisiran (siRNA): Novel, twice-yearly injection for long-term adherence.

Takeaway: A stratified, stepwise approach—from oral combinations to advanced injectables—ensures more patients achieve and maintain their LDL-C goals.
References: Mach F, et al. 2025 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2025.
#Cardiology #ESC2025 #Lipidology #LDL #Atherosclerosis #StatinIntolerant #PCSK9 #Inclisiran

No photo description available.
← newer: Humming boosts nasal nitric oxide about 15-fold; a small RCTolder: Only lipophilic statins like atorvastatin enter the brain; P →